Toll Like Receptors Signaling Pathways as a Target for Therapeutic Interventions

Author(s): Agnieszka Jezierska, Irina A. Kolosova, Alexander D. Verin

Journal Name: Current Signal Transduction Therapy

Volume 6 , Issue 3 , 2011

Become EABM
Become Reviewer


This review summarizes the key role of Toll-Like Receptor (TLRs) molecules for igniting the immune system. Activated by a broad spectrum of pathogens, cytokines or other specific molecules, TLRs trigger innate immune responses. Published data demonstrate that the targeting and suppression of TLRs and TLR-related proteins with particular inhibitors may provide pivotal treatments for patients with cancer, asthma, sepsis, Crohns disease and thrombosis. Many drugs that target cytokines act in the late phases of the activated pathways, after the final peptides, proteins or glycoproteins are formed in the cell environment. TLR activity occurs in the early activation of cellular pathways; consequently inhibiting them might be most beneficial in the treatment of human diseases.

Keywords: TLR, signaling pathways, therapy, Endocytosis, Gefitinib, Endosomes, Lysosomes, Nucleus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [428 - 440]
Pages: 13
DOI: 10.2174/157436211797483930
Price: $65

Article Metrics

PDF: 10